Dermapharm Holding SE buy Sargnagel
Start price
10.07.21
/
60%
€69.00
Target price
10.07.22
-
Performance (%)
-25.94%
End price
11.07.22
€51.10
Summary
This prediction ended on 11.07.22 with a price of €51.10. The price of Dermapharm Holding SE has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -25.94%. Sargnagel has 60% into this predictionDermapharm Holding is a Munich-based pharmaceutical company that develops innovative drug formulations and medical devices. It is listed on the Frankfurt Stock Exchange and has a strong presence in Germany and Europe. The company's product portfolio includes preparations for both prescription and over-the-counter drugs, as well as medical devices used in dermatology and urology. Dermapharm Holding differentiates itself from competitors by focusing on niche markets and developing new products in-house through its research and development activities.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Dermapharm Holding SE | -0.695% | -0.695% | -17.246% | -46.073% |
| iShares Core DAX® | -0.116% | 1.953% | 14.155% | 16.268% |
| iShares Nasdaq 100 | -2.733% | -1.273% | 31.828% | 43.377% |
| iShares Nikkei 225® | -1.721% | 3.263% | 12.922% | 8.501% |
| iShares S&P 500 | -1.527% | 0.194% | 27.117% | 41.752% |
According to Sargnagel what are the pros and cons of Dermapharm Holding SE for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Capable Management
Differentiated customer and product portfolio
Growths faster than the competition
Medium risks for its business
Cons
Few uniques
Comments by Sargnagel for this prediction
In the thread Dermapharm Holding SE diskutieren
Buy Dermapharm Holding SE
In the thread Trading Dermapharm Holding SE
Die von Sargnagel gewählte maximale Laufzeit wurde überschritten